Intravitreal Aflibercept or Ranibizumab for Rubeosis Iridis

Sponsor
Instituto de Olhos de Goiania
Study ID
NCT02641457
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - 65 Years
Healthy Volunteers
Accepted

Interventions

  • Aflibercept — DRUG
    12 eyes received an intraocular injection of 2.00 mg of aflibercept (IA) and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.
  • Ranibizumab — DRUG
    12 eyes received an intraocular injection of 1.25mg ranibizumab and IOP were measured by tonometer. The neovascularization was evaluated by biomicroscope.

Study Details

Aflibercept (Eylea®) and ranibizumab (Lucentis®) are an anti-VEGF, but there are differences between the two drugs. To determine and compare whether intraocular aflibercept and ranibizumab decreases rubeosis iridis (RI) in patients with neovascular glaucoma (NVG).

Key Dates

Start date
Mar 31, 2014
Status verified
Dec 2015
Primary completion
Mar 31, 2015
Completion
Oct 31, 2015

Study Design

Enrollment
2 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Aflibercept x Ranibizumab
    12 eyes received an intraocular injection of 2.00 mg of aflibercept (IA) and 12 eyes patients received an intraocular injection of 1.25mg ranibizumab

Primary Outcome Measure

Degree of rubeosis iridis by biomicroscope [ Time Frame: 1 year follow up ]

Related Studies